This study establishes an association between pre-treatment LAG-3, CD8, STAT1, and LAG-3+CD8+ tissue expression and responsiveness to monoclonal antibody immunotherapy in patients with advanced HCC, with the LAG-3+CD8+ cell proportion being the most favorable protein biomarker. This evidence concerns the gene CD8A and hepatocellular carcinoma.